Use of pharmacogenomic testing enables physicians to ensure that the safest, most effective medications are prescribed to every patient, reducing trial and error prescribing and improving treatment outcomes.
The U.S. Food and Drug Administration has approved a new tablet for use in helping patients with opioid dependence.
Canaglifozin (Invokana, Janssen Pharmaceuticals) tablets, recently approved by the U.S. Food and Drug Administration for the improvement of glycemic control in adults with type 2 diabetes, is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 inhibitors.
Use of drugs that inhibit gastric acid is linked to a higher risk of hip fracture among patients, new research shows.
Risk of GI complications due to NSAID use varies by specific drug and by dosage, according to research.
The U.S. FDA has approved a REMS to educate practitioners and patients about potential for side effects associated with unapproved treatment quinine for prevention of nocturnal leg cramps.
Although use of nutraceuticals and nonprescription over-the-counter drugs may be high among patients, cardiologists and cardiologists in training may largely ignore the use of these agents among patients, according to new research.
Patients with chronic obstructive pulmonary disease exacerbations treated with low-dose oral corticosteroids have outcomes similar to those treated with more costly and invasive high-dose intravenous corticosteroid therapy, according to new research.
Parkinson's disease patients taking the drug amantadine are at risk for damage to the corneal endothelium and resulting impaired vision, which can become more pronounced the longer the drug is used, according to research.
Use of antidepressants during pregnancy, particularly paroxetine, venlafaxine, or a combination of different antidepressant classes, may increase risk of miscarriage by 68 percent, according to researchers.